The Death of Advertising
Zander Nethercutt

Good work, Zander! I just came across it and as I have a directionally similar piece coming up tomorrow, I made sure to include a link.

One pushback though: Some markets will still be leanings towards scale and the median user. Pharmaceuticals, which you mention, are a good example. The necessary upfront investment in research leads to a situation where creating super-focused, longtail products not profitable. That’s why research into many rare illnesses doesn’t get proper funding.

That being said, yes, the general direction is certainly right.

One clap, two clap, three clap, forty?

By clapping more or less, you can signal to us which stories really stand out.